The partnership will integrate Ocuco’s optical software solution, Acuitas 3, with Nextech’s Ophthalmic Platform.

A study analyzed the geographic and institutional disparities in clinical trial distribution for candidates targeting the ...

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to ...

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after ...

The US Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for ...

Researchers from the Czech Republic found that an AI system showed higher sensitivity and specificity for screening diabetic ...

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

With a range of treatments available for presbyopia, the challenge for clinicians is to guide patients toward the most ...

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment ...

Tertiary syphilis, which can develop years to decades after the initial infection, is characterized by chronic inflammatory ...

BRIMOCHOL PF’s combination of brimonidine and carbachol produces a “pinhole effect,” which is intended to improve depth of ...

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.